Balyasny Asset Management
MRVI icon

Balyasny Asset Management’s Maravai LifeSciences MRVI Stock Holding History

Balyasny Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-141,100
Closed -$3.6M – 3058
2022
Q3 		$3.6M Buy
+141,100
New +$3.54M 0.01% 1185
2022
Q2 		– Sell
-10,000
Closed -$353K – 3013
2022
Q1 		$353K Hold
10,000
– – ﹤0.01% 1887
2021
Q4 		$419K Buy
+10,000
New +$405K ﹤0.01% 1662

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management's MRVI Position: Q4 2025 in Review

Balyasny Asset Management sold out of Maravai LifeSciences (MRVI) in Q4 2025, closing a stake of 35,821 shares — an estimated $103K sold.

Balyasny Asset Management first reported a position in MRVI in Q4 2020 and held it in 13 quarters. The position peaked at $28M in Q4 2020. 159 funds tracked by Wall St. Rank hold MRVI as of Q4 2025.

  • Balyasny Asset Management reported no remaining Maravai LifeSciences position as of Q4 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 35,821 Maravai LifeSciences shares in Q4 2025, an estimated $103K.
  • Balyasny Asset Management first reported a position in Maravai LifeSciences in Q4 2020 and held it in 13 quarters.
  • Balyasny Asset Management's Maravai LifeSciences position peaked at $28M in Q4 2020.
  • 159 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.